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“Why do we age?”; “Can we intervene in the aging 
process?”; and if so, what approaches should aging 
science take to transform research into viable 
therapeutic interventions to improve public health? 
Understanding the mechanisms of aging will be of vital 
importance to answering these questions. However, 
several obstacles stand in the way of generating 
efficacious and safe interventions that extend the period 
of healthy life.   
 
At the 5th Annual Aging and Drug Discovery Forum 
which was held during the Basel Life Congress, Basel, 
Switzerland, September 12-13, 2018, leading aging 
experts from academia and industry came together to 
discuss top issues in aging research. The meeting was 
organized by Alex Zhavoronkov, CEO of Insilico 
Medicine (Baltimore, MD, United States), a company 
specialized in implementing artificial intelligence (AI) 
solutions for drug discovery and biomarker 
development and Morten Scheibye-Knudsen, head of 
the aging interventions lab at the Center for Healthy 
Aging, University of Copenhagen (Copenhagen, 
Denmark). Here, we provide a brief overview of the 
presented results and discussion points.  
 
What drives the aging process? 
 
Aging is a multifactorial process that leads to loss of 
cellular homeostasis followed by susceptibility to 
diseases. The functional decline is influenced by highly 
conserved signaling pathways that could be targeted to 
manipulate the aging process. Judith Campisi from the 
Buck Institute for Research on Aging (Novato, CA, 
United States) highlighted the impact of cellular 
senescence as an evolutionary balancing act on aging 
[1]. Senescent cells accumulate over time and promote 
the aging processes by loss of tissue functionality and 
through the secretion of pro-inflammatory factors, 
















represents a double-edged sword by repressing 
malignant transformation. However, accumulation over 
time causes degenerative phenotypes and drives tumor 
formation. Therefore, targeting senescent cells using 
senolytics or by compensating for the beneficial effects 
of the induced secretory phenotype, may help to prevent 
age-dependent functional decline. Clear markers for 
senescent cells are still lacking, due to the strong 
heterogeneity of senescent cells [3,4]. To address this 
issue, the group of Judith Campisi implemented single 
cell analysis to further understand the cell-type specific 
signatures of senescent cells, which may help to find 
more specific targets [4].  
 
Michael Ristow from the ETH Zürich (Zürich, 
Switzerland) presented his work about redox-regulation 
of lifespan and metabolism. Previous results of his 
group suggest the concept of mitohormesis as a health-
promoting signaling pathway, where low concentrations 
of reactive oxygen species (ROS) lead to an adaptive 
response [5]. The concept of mitohormesis was further 
supported by the observation that glucose restriction in 
C. elegans leads to increased ROS production, thereby 
promoting endogenous stress defense and increased 
lifespan [6]. ROS-induced increased insulin sensitivity 
was also observed in a physical exercise trial in humans 
and, interestingly, this effect was inhibited by the 
supplementation of antioxidants [7]. Furthermore, his 
group compared gene expression levels of young, 
mature and old C. elegans, D. rerio and M. musculus to 
predict evolutionary conserved age-related genes. 
Branched-chain amino acid transferase 1 (bcat-1) was 
identified as a strong lifespan regulator and, accor-
dingly, knockdown of bcat-1 increased lifespan in C. 
elegans [8].  
 
Both endogenous stress factors, such as ROS and 
exogenous stress factors are constantly challenging the 
human genome. Different DNA repair pathways have 
evolved to repair the different DNA lesions. Indeed, 




Both  industry and academia are  therefore exploring possible  transformative molecules  that  target aging and
age‐associated diseases.  In this overview, we summarize the presented talks and discussion points of the 5th
Annual  Aging  and  Drug  Discovery  Forum  2018  in  Basel,  Switzerland.  Here  academia  and  industry  came
together,  to  discuss  the  latest  progress  and  issues  in  aging  research.  The meeting  covered  talks  about  the
mechanistic cause of aging, how longevity signatures may be highly conserved, emerging biomarkers of aging,
possible  interventions  in  the  aging process  and  the use of  artificial  intelligence  for  aging  research  and drug
discovery.  Importantly,  a  consensus  is  emerging  both  in  industry  and  academia,  that  molecules  able  to
intervene in the aging process may contain the potential to transform both societies and healthcare. 
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capacity has been suggested to decline with age [9]. The 
impact of DNA repair on aging was emphasized by two 
presentations at the meeting. Morten Scheibye-
Knudsen from the University of Copenhagen 
(Copenhagen, Denmark) discussed the phenotypical 
landscape of aging [10] and emphasized that the 
mechanisms causing the different pathologies of aging 
are poorly understood. Morten Scheibye-Knudsen 
presented the value of using hierarchical clustering and 
machine learning algorithms to compare similarities 
between diseases based on their clinical features [11]. 
This approach may help to find cellular pathways that 
are linked to specific disease pathologies. Notably, 
diseases caused by defects in DNA repair resembles 
many features of aging, emphasizing genome mainte-
nance as a key factor of aging [12]. Thus, premature 
aging disorders may be good model systems to study 
aging.  
 
This observation was underscored by Martijn 
Luijsterburg from the Leiden University Medical 
Center (Leiden, The Netherlands) who presented his 
latest research on transcription-coupled DNA repair, a 
DNA repair pathway that removes lesions blocking 
transcription of active genes. Interestingly, mutations in 
transcription-coupled repair genes are known to cause 
diverse phenotypes [13]. Mutations in CSA and CSB 
can cause the premature aging disorder Cockayne 
syndrome which is characterized by severe neuro-
degeneration, whereas mutations in UVSSA can cause 
the UV-sensitivity syndrome, a disease without neuro-
logical phenotypes. Untangling the precise molecular 
functions of the transcription coupled repair complex 
members may help to understand the disease mecha-
nism of Cockayne syndrome and aging features. Martijn 
Luijsterburg presented his latest results towards this 
understanding.  
 
Signatures of longevity 
 
In recent years, a concerted effort was made to identify 
biological markers that can predict the chronological 
age of an individual. Different types of age predictors 
including telomere length [14], gene expression changes 
[15] and epigenetic changes, the latter known as the 
epigenetic clock [16–18], have been shown to strongly 
correlate with chronological aging. Vadim Gladyshev 
from the Brigham and Women’s Hospital, Harvard 
Medical School (Boston, MA, United States) and 
Moscow State University (Moscow, Russia) highlighted 
that the combination of different approaches can allow 
for more reliable biological age prediction, since aging 
is a systemic process. His research group investigated 
the mouse blood DNA methylome of different age 
groups to develop an epigenetic clock that can be used 
to test aging interventions [19]. Notably, this analysis 
showed that caloric restriction, as well as the long-lived 
mutant Snell dwarf mice, exhibit slower epigenetic 
aging. A further study of his group determined 
longevity-related transcriptomic changes across 33 
species of mammals [20] and 14 different Drosophila 
species [21], which may be used for prediction of new 
longevity interventions. 
 
Collin Ewald from the ETH Zürich (Zürich, 
Switzerland) presented his recent work on the 
transcriptomic signatures of longevity in C. elegans, 
revealing that the extracellular matrix (ECM) composi-
tion undergo changes with age. Notably, potential aging 
interventions, such as rapamycin treatment, modulate 
ECM gene expression [22]. Moreover, reduced 
insulin/IGF-1 signaling induced lifespan extension was 
shown to be dependent on collagen gene expression. 
These observations indicate that modulation of the 
ECM may be a promising target. Collin Ewald’s work 
reveals the value of C. elegans as a powerful model 
system to study aging and aging interventions, due to its 
relatively short life span and easily manipulated 
genome.   
 
In addition to epigenetic and gene expression changes, 
profound age-dependent remodeling of protein 
expression can be observed with age [23]. Stuart 
Maudsley from the University of Antwerp (Antwerp, 
Belgium) discussed the identification of multidimen-
sional regulators of aging.  In several recent studies, his 
group has examined, using a combination of classical 
signaling pathway analysis and natural language 
processing informatics, age-related proteomic altera-
tions in the hypothalamus, the potential key organ that 
coordinates global somatic aging [24]. Using this novel 
approach, the G protein-coupled receptor kinase 
interacting protein 2 (GIT2) was identified as a potential 
key regulator of aging. Consequently, GIT2 protein 
expression was demonstrated to be strongly age-
sensitive in the hypothalamus and multiple other brain 
regions as well as a broad range of peripheral tissues 
associated with energy metabolism regulation [24,25]. 
GIT2 acts a scaffold protein for multiple signaling 
pathways, hence decreased GIT2 function affects 
several hallmarks of aging including metabolic dys-
function [25], DNA damage responses [26], oxidative 
damage responsiveness [27] and immune system 
senescence [28]. Thus, GIT2 may be a promising 
multidimensional therapeutic target for age-associated 
diseases [29,30].  
 
Interventions in aging and aging-associated disease 
 
In the last years multiple interventions for life span 
extension have been identified. Pharmacological (e.g. 
rapamycin, resveratrol, metformin) and non-pharma-
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cological interventions (e.g. caloric restriction, physical 
exercise) have been extensively discussed. Never-
theless, how these interventions may affect human 
health span is not well understood. A growing number 
of studies suggest that the macronutrient composition of 
the diet, and in particular dietary protein, may also play 
a crucial role in regulating metabolic health and life 
span [31]. However, it remains an open question as 
whether altered consumption of specific dietary amino 
acids mediates the beneficial effects of reduced dietary 
protein. In this regard, Dudley Lamming from the 
University of Wisconsin (Madison, WI, United States) 
presented his work about promoting healthy aging 
through the reduction of specific dietary macronutrients. 
Dudley Lamming’s research group provided data 
revealing that the reduction of branched chain amino 
acids improved metabolic health in lean as well as diet-
induced obese C57BL/6J mice, and recapitulated many 
of the metabolic benefits of a low protein diet [32,33]. 
Notably, a reduction of leucine alone stimulated white 
adipose tissue growth, indicating that individual 
branched-chain amino acids may have distinct roles in 
the regulation of metabolic health [33].   
  
Due to the difficulty to reduce caloric intake, com-
pounds mimicking the positive effects of caloric 
restriction may be a promising strategy, as outlined by 
Joseph Baur from the University of Pennsylvania 
(Philadelphia, PA, United States). Modulating nicotin-
amide adenine dinucleotide (NAD+) levels is a 
promising strategy to treat age-associated physiological 
decline [34,35]. Recent work from Joseph Baur 
revealed that muscle specific knockout of nicotinamide 
phosphoribosyltransferase (NAMPT), an enzyme that is 
essential for the maintenance of normal NAD+ 
concentration, lead to progressive loss of muscle 
function. The observed phenotype was counteracted by 
administration of the NAD+ precursor nicotinamide 
riboside [36]. Interestingly, lifelong NAMPT over-
expression prevented the age-related loss of NAD+ and 
improved exercise performance in old mice. Although 
mitochondrial NAD+ pools have been shown to 
contribute to cell metabolism, the source of mito-
chondrial NAD+ remains an obscurity. A recently 
published study by the group of Joseph Baur proposes 
the existence of a so far undiscovered mitochondrial 
NAD+ transporter, which may be a further potential 
target to modulate the compartmentalization of NAD+ 
within the cell [37].  
 
Alexey Moskalev from the Moscow Institute of Physics 
and Technology (Moscow, Russia) emphasized the 
potential of natural compounds as aging interventions. 
Alexey Moskalev presented data about a potential 
geroprotective function of the carotenoid fucoxanthin in 
C. elegans and D. melanogaster [38]. Fucoxanthin 
increased the median lifespan of C. elegans and D. 
melanogaster, along with changes associated with aging 
such as increased stress resistance. At the molecular 
level the response to fucoxanthin in D. melanogaster 
goes along with transcriptional changes of longevity-
related signaling pathways, such as the MAPK, mTOR 
and autophagy pathways [39]. Preliminary data on 
human fibroblasts shows antisenogenic effects of 
fucoxanthin at 100 nM and 1 nkM (unpublished).  
 
Olga Kovalchuk from the University of Lethbridge and 
PathwayRx Inc. (Lethbridge, Canada) gave an overview 
of skin aging driven by intrinsic and extrinsic factors 
leading to deregulated matrix metalloproteinases 
(MMPs), enzymes activated by UV exposure, inflam-
mation and other factors [40]. MMPs contribute to the 
breakdown of collagen while inhibiting new collagen 
formation, and cytokine deregulation could be possible 
intervention targets by novel extracts. She gave an 
overview of the effects of UV and THz radiation on 
skin, and presented novel (patent pending) plant extracts 
with very potent anti-inflammatory and anti-aging 
capacities that can be used to counteract harmful 
environmental effects of skin and potentially reverse 
skin aging. 
 
Alejandro Martín-Montalvo from the Andalusian 
Molecular Biology and Regenerative Medicine Centre -
CABIMER- (Seville, Spain) discussed the potential of 
interventions based on the use of thyroid hormones on 
aging and age-associated diseases. The key role of 
thyroid hormone levels in regulating longevity is 
corroborated by the observation, that humans with 
exceptional longevity, and other long-lived animals, 
show decreased circulating thyroid hormone levels [41]. 
Nevertheless, Alejandro Martín-Montalvo showed that 
thyroid hormones enhance glucose clearance, leading 
him to investigate if these hormones could be used for 
the treatment of different types of diabetes. Indeed, his 
team has shown, using two experimental models of 
diabetes, that thyroid hormones efficiently blunt the 
onset of diabetes and increase survival in mice [42]. The 
data indicate a potential benefit of thyroid hormones 
and/or thyromimetics for the treatment of type 1 
diabetes mellitus. 
 
The power of AI to facilitate anti-aging drug 
discovery  
 
In comparison to conventional drug development, the 
development and commercialization of pharmaceuticals 
targeting aging pose additional difficulties. Alexander 
Pickett (Juvenescence Ltd, Boston, MA, United States), 
SVP of Business Development at Juvenescence 
Limited, a drug development company focusing on 
therapeutics that modify aging, highlighted the 
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obstacles to developing aging interventions. The lack of 
reliable techniques to prove the efficacy of the 
therapeutics is one of the main difficulties of clinical 
trial designs for aging interventions. In this regard, 
Alexander Pickett pointed out the importance of 
developing new reliable biomarkers and validating that 
they were not only predictive of aging but also 
responded to known interventions. Another obstacle 
will be commercializing aging intervention drugs: so 
far, our health care systems rely predominantly on 
treating illness rather than keeping people healthy. 
Juvenescence believes that developing aging inter-
ventions to treat existing diseases and seeking 
outcomes-based reimbursement is the quickest path to 
bringing aging interventions to large populations. To 
address these issues, Juvenescence Limited has invested 
in several biotech startups that pursue a whole range of 
approaches, including Insilico Medicine.   
 
Ivan Ozerov from Insilico Medicine (Baltimore, MD, 
United States) introduced an AI-driven computational 
pipeline approach to identify new small molecules that 
counteract the progression of cellular senescence. The 
approach relies on the concept of 5R (Rescue, Remove, 
Replenish, Reinforce, Repeat) and utilize the recently 
published in silico Pathway Activation Network 
Decomposition Analysis (iPANDA) method [43]. The 
pipeline may accelerate target and drug discovery for 
anti-aging interventions.  
 
The power of Artificial Intelligence to facilitate drug 
discovery was highlighted further by Garik Mkrtchyan 
from the Scheibye-Knudsen lab (Copenhagen 
University, Denmark). Increased unrepaired DNA 
lesions are a hallmark of aging. To counteract this, 
stimulating DNA repair may be a promising approach. 
Garik Mkrtchyan presented work about deep learning 
algorithms utilized to screen a small molecule library to 
identify compounds that stimulate DNA repair. The 
success of the approach was proven by the identification 
of drugs that induced cellular resistance to ionizing 
radiation but do not cause DNA damage (unpublished 
data).    
 
S. Jay Olshansky from the University of Illinois 
(Chicago) and co-founder of Lapetus Solutions, Inc., 
further emphasized the requirement of biomarkers to 
facilitate the identification of aging interventions. He 
made a point that the target of intervention should be 
healthspan and not lifespan [44]. Olshansky showed that 
biological age is reflected in facial features and 
underlined the value of photographic phenotypic 
biomarkers in health assessment. Based on facial 
photographs, age and gender can be predicted with a 
high degree of reliability, but also further risk factors 
such as smoking behavior and body mass index can be 
revealed, which makes it relevant to insurance and 
financial sectors as well. Facial analytics as a promising 
biomarker for aging, was further acknowledged by 
Anastasia Georgievskaya, a co-founder of Youth 
Laboratories (Moscow, Russian Federation). Youth 
Laboratories is using artificial intelligence to study 
aging and discover new class of non-invasive photo-
graphic aging biomarkers. Currently, the company is 
collecting photographs of lab mice to develop the first 
photographic biomarker for mice. Since mice are still 
the main model of aging research, the photographic 
mouse aging clock may facilitate the identification of 
beneficial aging interventions in mice to further 
translate them to humans. 
 
Panel discussion on key trends in longevity 
biotechnology 
 
The panel discussion on longevity biotechnology 
industry with Vadim N. Gladyshev, Morten Scheibye-
Knudsen, Judith Campisi, Alexander Pickett, Michael 
Antonov, Joseph A. Baur and Stuart Maudsley and 
chaired by Alex Zhavoronkov, identified the following 
areas with the most potential of commercialization: 
repurposing of drugs that are already on the market, 
senolytics, mTOR inhibitors, NAD+ activators and 
modulators, reprogramming-based and regenerative-
based approaches, AI and data analysis, and digital 
health. 
 
During the discussion, the panel highlighted the great 
potential of drug repurposing (repositioning) for aging 
research. Drug repurposing or target extension allows 
the identification of new indications for drugs with low 
safety risk profiles, as they have been already tested in 
humans. Great progress has been made in developing 
approaches for drug characterization and classification 
that could be used for drug repurposing [45–47]. 
Indeed, several attempts have been made to predict a 
potential aging application of existing medications [48–
52].  
 
Recently, several senolytics, selective inductors of 
senescence cell death, have been tested as aging 
preventive or aging revertive agents [53,54]. At the 
same time, the panel emphasized that such therapies 
have high-risk profiles, as they are only in early phases 
of clinical development [55]. mTOR inhibitors [56] and 
NAD+ activators [57,58] have also been listed as 
interventions that could delay the onset of multiple age-
related pathologies. Therefore, they could be explored 
as human aging therapies in the nearest future. One 
panelist made the point that regenerative medicine 
approaches [59] could provide therapeutic possibilities 
for targeting aging and could be developed further to 
reach the market. 
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AI and deep learning are now recognized as 
transformative technologies in healthcare in general 
[47,60,61]. For instance, a lot of progress has been 
made in machine-learning-based biomarkers of human 
aging using easily obtained data such as methylation 
[16,17], transcriptomics [62], proteomics [63] and blood 
biochemistry [64,65]. Following an extensive discus-
sion, panelists selected AI and digital health as key 
developments that would catalyze the pace of 
innovation in aging research. All panelists agreed that 
aging research and longevity interventions have 
tremendous opportunities to impact the whole health-




Clearly, aging interventions require a multifaceted 
approach through which complex phenotypes can be 
evaluated using next generation machine learning 
approaches. The meeting underscored the awareness 
that drug discovery in the aging field will require not 
only determination from academic researchers but also 
multiple industrial partners and investors. This state of 
the field is particularly clear in light of the significant 
number of emerging companies that attempt to tackle 
the task of finding translatable interventions into aging. 
It is evident from the formation of all these startups that 
the next promising longevity pharmaceuticals will be 
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